Guidelines
IV to PO Conversion

IV to PO Conversion

General Information

  • Evidence has shown that early conversion from intravenous (IV) to oral (PO) antimicrobial therapy is safe and effective for a variety of infections and a natural sequence in patient care
  • Potential benefits of early IV to PO conversion include increased patient comfort, decreased risk of line-related phlebitis and infection, decreased drug cost, decreased nursing administration time and facilitation of an early hospital discharge

Additional Information

Content derived from: NB-ASC. Antimicrobial Route of Administration (IV to PO) Therapeutic Conversion. 2020-03

  1. Capital Health Antimicrobial Handbook – 2012. Editor: Dr K. Slayter. Antimicrobial Agents Subcommittee, District Drugs and Therapeutics Committee.
  2. The Antimicrobial Handbook Guidelines, Policies and Treatment Recommendations – 2012. Editor: Bill Cornish. Antimicrobial Subcommittee of the Pharmacy and Therpeutics Committee, Sunnybrook Health Sciences Centre
  3. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003237
  4. Athanassa Z, Makris G, Dimopoulous G et al. Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Aquired Pneumonia a Meta Analysis. Drugs 2008;68(217):2469-2481
  5. Mertz D, Koller M, Haller P et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009 Jul;64(1):188-99
  6. Edmunds P, Ryan J, Glennie H, Sauerteig J, LeBlanc JM. Development of a Sustainable Parenteral To Oral Antimicrobial Monitoring Protocol. Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, Ontario, 2009.
  7. Hunter KA, Dormaier GK. Pharmacist-managed intravenous to oral step-down program. Clinical Therapy. 1995 May-Jun; 17(3):534, 40; discussion 516.
  8. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from IV to oral. American Journal of Health Syst Pharm. 2002 Nov 15; 59(22):2209-15.
  9. McLaughlin CM, Bodasing N, Boyter AC, Fenelon C, Fox JG, Seaton RA. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: An intervention study. QJM. 2005 Oct; 98(10):745-52.
  10. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999 Nov 8; 159(20):2449-54.
  11. DRUGDEX (drug monographs). Accessed 03/2019
  12. Lexi-Comp Drug Information (drug monographs) Accessed 03/2019
  13. Sanford Guide - electronic version (drug monographs) Accessed 03/2019
  14. John Hopkins ABX guide – electronic version (drug monographs) Accessed 06/2019
  15. Kuper, K.M. (2008). Intravenous to oral therapy conversion. In Murdaugh, L.B., Competence Assessment Tools for Health-System Pharmacies (4th ed.) (pp. 347-360). Bethesda: ASHP.
  16. NB-ASC. IV to PO e-learning module – electronic version. Accessed 03-2019
  17. Nova Scotia Health Authority. Pharmacist Initiated IV to PO Conversion of Antimicrobials Policy. 2017
  18. Sick Kids. IV to PO Conversion Recommendations. 2016
  19. The Scarborough Hospital. Antimicrobial IV to PO Sequential Therapy. 2012
  20. Vancouver Coastal Health. Pharmacist Managed IV-PO Conversion Program. 2013